In CONCERTO-@ , prior non-responders to IFN-based therapy ( N = @ ) received simeprevir ( TMC@ ) @ mg QD with PR for @ ( SMV@ , n = @ ) or @ weeks ( SMV@ , n = @ ) followed by response-guided therapy ( RGT ) with PR for @/@ ( SMV@ ) or @/@ ( SMV@ ) weeks .